Determination of vital status at the end of the DIG trial

Area of Science:

• Cardiology
• Clinical Trials
• Pharmacology

Background:

• Heart failure affects millions globally, necessitating effective treatments.
• Digoxin is a common medication for heart failure, but its impact on mortality requires clear definition.
• The Digitalis Investigation Group (DIG) trial aimed to resolve uncertainties regarding digoxin's role in heart failure management.

Purpose of the Study:

• To determine the effect of digoxin on total mortality in patients with heart failure.
• To assess whether digoxin provides benefit, harm, or no effect on mortality in this patient population.
• To establish definitive evidence for digoxin's efficacy and safety in heart failure management.

Main Methods:

• A large-scale, randomized, double-blind, placebo-controlled trial.
• Inclusion criteria: heart failure, sinus rhythm, ejection fraction ≤0.45.
• Rigorous data collection and closeout procedures to ensure complete vital status data.

Main Results:

• The DIG trial successfully determined the vital status for over 98.8% of participants.
• This high completion rate minimized potential bias from missing data.
• The study design facilitated accurate reporting of outcomes.

Conclusions:

• The DIG trial established a robust methodology for large clinical trials with common end dates.
• The study's success underscores the importance of proactive planning for data acquisition and study closeout.
• Recommendations for future trials emphasize early activation of data collection plans to ensure data completeness.